Phase II GeparNUEVO: Survival Outcomes With Durvalumab + Neoadjuvant CT vs Placebo + Neoadjuvant CT in Early TNBC

June 4-8, 2021; Online at
In this analysis of survival outcomes at a median follow-up of approximately 3.5 years, the addition of durvalumab to neoadjuvant CT significantly prolonged iDFS, distant DFS, and OS vs placebo + neoadjuvant CT in patients with early TNBC.
Format: Microsoft PowerPoint (.ppt)
File Size: 453 KB
Released: June 10, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.

Related Content

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v3.2021, from CCO

Released: July 22, 2021

On-demand webcast from a live Clinical Care Options (CCO) webinar with global expert perspectives on CDK4/6 inhibitors for early-stage HR+/HER2- breast cancer

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 21, 2021 Expired: July 20, 2022

From Clinical Care Options (CCO), video of pharmacist discussion of recently approved agents targeting HER2 and TROP2 for metastatic cancers

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Allison Butts, PharmD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 20, 2021 Expired: July 19, 2022

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: July 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.